By: Patrick Lavery
Inmazeb is a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn. October 26, 2026
Patrick Lavery is an Editor for the MJH Life Sciences brands Pharmaceutical Technology and BioPharm International. He specializes in topics such as gene therapy, pharmaceutical manufacturing, and regulation, as well as digital health and telehealth advancements. Patrick's work has been featured in LCGC, Spectroscopy Media, New Jersey 101.5 Radio, BioPharm International, PharmTech, The National Law Review, JD Supra, Contract Pharma, and Pharmaceutical Executive.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .